IMVT vs. MRNA, ASND, VTRS, QGEN, BPMC, ROIV, RVMD, BBIO, ELAN, and VRNA
Should you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), and Verona Pharma (VRNA). These companies are all part of the "pharmaceutical products" industry.
Immunovant vs. Its Competitors
Moderna (NASDAQ:MRNA) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability.
75.3% of Moderna shares are held by institutional investors. Comparatively, 47.1% of Immunovant shares are held by institutional investors. 11.0% of Moderna shares are held by company insiders. Comparatively, 5.9% of Immunovant shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Immunovant has lower revenue, but higher earnings than Moderna. Immunovant is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.
Moderna presently has a consensus target price of $46.61, indicating a potential upside of 67.97%. Immunovant has a consensus target price of $38.33, indicating a potential upside of 137.36%. Given Immunovant's stronger consensus rating and higher probable upside, analysts clearly believe Immunovant is more favorable than Moderna.
Immunovant has a net margin of 0.00% compared to Moderna's net margin of -110.04%. Moderna's return on equity of -28.74% beat Immunovant's return on equity.
In the previous week, Moderna had 9 more articles in the media than Immunovant. MarketBeat recorded 17 mentions for Moderna and 8 mentions for Immunovant. Immunovant's average media sentiment score of 1.30 beat Moderna's score of 0.51 indicating that Immunovant is being referred to more favorably in the news media.
Moderna received 84 more outperform votes than Immunovant when rated by MarketBeat users. However, 77.19% of users gave Immunovant an outperform vote while only 53.07% of users gave Moderna an outperform vote.
Moderna has a beta of 1.86, indicating that its share price is 86% more volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.
Summary
Moderna beats Immunovant on 9 of the 17 factors compared between the two stocks.
Get Immunovant News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Immunovant Competitors List
Related Companies and Tools
This page (NASDAQ:IMVT) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy IMVT Stock Free IMVT Stock Alerts